title: [Macular translocation - a therapeutic approach for neovascular macular degeneration in the era of anti-VEGF therapy?].
abstract: Since anti-VEGF treatment has been proven to achieve a significant improvement of visual acuity in a cohort of patients with neovascular age-related macular degeneration (AMD), macular surgery and particularly the macular translocation with 360 degrees retinotomy (FMT: full macular translocation) have lost their former popularity. However, the approach of macular surgery still remains a promising therapy in selected cases. A prospective randomised study, comparing FMT and photodynamic therapy in subfoveal classic choroidal neovascularisation (CNV), recently showed the superiority of FMT in terms of visual gain. In spite of the postoperative complications and the disturbed binocular vision, the reading acuity and the life quality of many patients improved. Therefore, it is justified to discuss the chances and advantages of the FMT at least in selected cases. After all, case selection was an important determinant also in the phase III studies of ranibizumab; many patients seen during the routine consulting hours were excluded as a consequence of the study criteria. Most of them were suspected to achieve a less favourable outcome of the anti-VEGF regimen. Thus, patients who did not meet the inclusion criteria of recent studies or showed no response to the anti-VEGF therapy, as well as patients with extensive submacular bleeding or ruptures of the pigment epithelium can also be considered as candidates of FMT. Generally, in the presence of highly effective anti-VEGF drugs, FMT can be discussed for second-line treatment, if the fellow eye has poor function and no additional risk factors of the affected eye are known (e. g., hyperopia, large lesion size, etc). Detailed information relating to the potential adverse events have to be mentioned. Although the indication is restricted, surgeons should have the continuing ability to perform the challenging surgical procedure.
authors.affiliation: Department für Augenheilkunde, Eberhard-Karls-Universität Tübingen.
authors.forename: F
authors.initials: F
authors.lastname: Ziemssen
authors.forename: F
authors.initials: F
authors.lastname: Gelisken
mesh_terms: D006801:Humans; D008266:Macula Lutea / Q000601:surgery*; D008268:Macular Degeneration / Q000188:drug therapy* / Q000601:surgery; D013508:Ophthalmologic Surgical Procedures / Q000379:methods*; D016032:Randomized Controlled Trials as Topic; D040262:Receptors, Vascular Endothelial Growth Factor / Q000037:antagonists & inhibitors*; D015861:Retinal Neovascularization / Q000188:drug therapy* / Q000601:surgery*
chemical_list: D040262:Receptors, Vascular Endothelial Growth Factor